About Cypress BioTech
Cypress BioTech, a subsidiary of Cypress Group LLC, is a Tennessee-based biotechnology company specializing in the discovery, synthesis, and analysis of therapeutic peptides. Our state‑of‑the‑art laboratory combines advanced analytical instrumentation with an experienced scientific team to accelerate peptide research from concept through pre‑clinical validation.
Current Research Focus
- Analytical & Stability Testing: HPLC, LC‑MS/MS, NMR, and forced‑degradation studies to verify quality and shelf‑life.
- Lead Optimization: Structure‑activity relationship (SAR) studies, peptide–protein docking, and bioavailability enhancement.
- Pre‑clinical R&D Support: In‑vitro assay development, cell‑based efficacy testing, and pharmacokinetic profiling.
Current Research Focus
We are actively pursuing peptide‑based solutions in the following therapeutic areas:
- Metabolic disorders – GLP‑1/GIP dual agonists and next‑generation incretins.
- Musculoskeletal repair – Collagen‑mimetic peptides for tendon and ligament healing.
- Inflammation modulation – Selective cytokine‑inhibiting peptide scaffolds.